| Project/Area Number |
15K19911
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Jikei University School of Medicine |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
SAITO Nobuhiro
SHIRAI Yoshihiro
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | IMiDs / 膵臓癌 / NF-κB / gemcitabine / nab-paclitaxel / アポトーシス / 細胞周期停止 / 血管新生抑制 / gemcitabine/nab-PTX / pomalidomide / NF-kB / apoptosis / cell cycle arrest / anti-angiogenesis / p53 / 免疫調節薬 / 膵癌 / 抗癌化学療法 / 免疫調節薬併用膵癌化学療法 |
|---|
| Outline of Final Research Achievements |
Anticancer drug-induced nuclear factor-kappa B (NF-κB) attenuates chemosensitivity. Gemcitabine and nab-paclitaxel is recommended for unresectable pancreatic cancer, however, the median survival time is only 8.5 months. Thalidomide suppresses NF-κB activation in digestive cancer, therefore, we hypothesized that pomalidomide, a third generation of IMiDs, also improve chemoresistance on pancreatic cancer cells.
For both in vitro and in vivo, pomalidomide enhanced the antitumor effects of gemcitabine/nab-paclitaxel and gemcitabine/S-1. Especially, to the best of our knowledge, current study firstly demonstrated that pomalidomide enhanced p53 on pancreatic cancer cells. Pomalidomide also induced apoptosis, cell cycle arrest, and anti-angiogenesis on pancreatic cancer. This new regimen would be a new therapeutic approach.
|
